Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

Rhabdomyosarcoma Clinical Trial

Official title:

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01871766
• Other study ID #: RMS13
• Secondary ID: NCI-2013-00913
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: December 4, 2013
• Est. completion date: June 2030

Study information

• Verified date: September 2023
• Source: St. Jude Children's Research Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will treat participants with newly diagnosed, low, intermediate and high risk rhabdomyosarcoma (RMS) using multi-modality risk-adapted therapy with standard or intensified dose chemotherapy, radiation and surgical resection. Intermediate and high risk participants will receive an additional 12 weeks (4 cycles) of maintenance therapy with anti-angiogenic chemotherapy.

PRIMARY OBJECTIVE:

• Estimate event-free survival for intermediate risk participants treated with vincristine, dactinomycin and cyclophosphamide with the addition of maintenance anti-angiogenic therapy.

SECONDARY OBJECTIVES:

• Estimate the false negative rate and incidence of additional positive lymph nodes in participants undergoing sentinel lymph node biopsy followed by limited nodal dissection.

• Maintain a high local control rate in participants treated with surgery and/or limited volume proton and photon radiation without dose escalation.

• Define the incidence and type of failure in participants who receive risk-adapted local therapy relative to the primary tumor volume.

• Establish the feasibility of delivering 4 cycles of maintenance anti-angiogenic chemotherapy in intermediate and high risk patients following standard chemotherapy.

• Estimate the event free survival for high risk patients receiving interval dose compressed therapy and maintenance anti-angiogenic therapy.

• Define the incidence of CTC grade 3 and higher toxicities (and specific grade 1-2 toxicities) related to proton beam therapy.

Description:

Participants will be stratified based on both a pretreatment staging system and a post-surgery surgico/pathologic clinical grouping system. Treatment for low-risk (subset 1) participants will consist of chemotherapy and radiation. Low-risk (subset 2) and intermediate-risk participants will receive chemotherapy and radiation and/or undergo surgery to destroy/remove the tumor. Intermediate-risk participants will also receive 16 weeks of maintenance chemotherapy. High-risk participants will receive chemotherapy and radiation therapy. High-risk participants will also receive additional maintenance therapy with anti-angiogenic chemotherapy.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 98
• Est. completion date: June 2030
• Est. primary completion date: July 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 21 Years

Eligibility

Inclusion Criteria:

• Newly diagnosed participants with localized rhabdomyosarcoma (RMS).

• Must have either low-, intermediate-, or high-risk disease, defined as:

• Low-risk: Embryonal, botryoid, spindle cell tumors only (Subset 1: Stage 1, Group I; Stage 1 Group I; Stage 1 Group III orbital only; Stage 2 Group I; Stage 2 Group II) (Subset 2: Stage 1 Group III non orbit; Stage 3 Group I, II)

• Intermediate-risk: Embryonal, botryoid, or spindle cell RMS Stage 2 or 3 and Group III; Alveolar, undifferentiated, or anaplastic RMS: Stage 1-3, group I-I; I)

• High-risk: Embryonal, botryoid, spindle cell, alveolar, undifferentiated, or anaplastic RMS with metastatic disease at diagnosis (stage 4).

• Participants treated on this protocol in the low or intermediate risk arm who experience disease progression prior to week 13 will transfer to the high risk arm and proceed with high risk chemotherapy starting at week 1 of the protocol.

• Age < 22 years (eligible until 22nd birthday)

• Performance level corresponding to ECOG score of 0, 1, or 2. The Lansky performance score should be used for participants < 16 years

• Participant has received no prior radiotherapy or chemotherapy for rhabdomyosarcoma (excluding steroids) unless an emergency situation requires local tumor treatment. Prior biopsy, surgical resection and lymph node sampling is allowed.

• Initiation of chemotherapy is planned within 6 weeks (42 days) of the definitive biopsy or surgical resection.

• Adequate bone marrow function defined as:

• Peripheral absolute neutrophil count (ANC) = 750/µL

• Platelet count = 75,000/µL (transfusion independent)

• Adequate liver function defined as total bilirubin = 1.5 x upper limit of normal (ULN) for age. Participants with biliary or hepatic primaries with bilirubin values greater than 1.5 x ULN may be enrolled on study if all other eligibility criteria are met.

• Adequate renal function defined as:

• Creatinine clearance or radioisotope GFR = 70 mL/min/1.732 or

• Serum creatinine based on age and gender

• Participants with urinary tract obstruction by tumor must meet the renal function criteria listed above AND must have unimpeded urinary flow established via decompression of the obstructed portion of the urinary tract.

• Patients requiring emergency radiation therapy are eligible for enrollment on this study.

• Females of child-bearing potential cannot be pregnant or breast-feeding. Female participants = 10 years of age or post-menarchal must have a negative serum or urine pregnancy test within 24 hours prior to beginning treatment. Female participants who are breast feeding must agree to stop breast feeding.

• Sexually active patients of childbearing potential must be willing to use effective contraception during therapy and for at least 1 month after treatment is completed.

• No evidence of active, uncontrolled infection.

• All participants and/or their parents or legal guardians must sign a written informed consent.

Exclusion Criteria:

• Participants who fail to meet one or more of the inclusion criteria will be excluded.

Inclusion Criteria for Contrast-Enhanced Ultrasound (CEUS) Sub-Study:

• Newly diagnosis or suspected diagnosis of previously untreated participants with rhabdomyosarcoma (RMS). NOTE: Patients with suspected diagnosis of RMS may enroll on screening part of study but must have histologic diagnosis to enroll on treatment part of study.

• Must have either intermediate-risk or high risk disease.

• 0-21 years of age.

Exclusion Criterial for CEUS Sub-Study:

• Undergoing upfront surgical resection of the primary tumor.

• History of allergy to Optison(TM) contrast agent or blood products.

Related Conditions & MeSH terms

• Rhabdomyosarcoma

Intervention

Drug:
• Vincristine
Dosage and route of administration: < 1 year of age=0.025 mg/kg intravenously (IV) > 1 year and < 3 years= 0.05 mg/kg IV = 3 years=1.5 mg/m^2 IV. Maximum dose 2 mg in all participants.
• Dactinomycin
Dosage and route of administration: < 1 year=0.025 mg/kg IV push = 1 year=0.045 mg/kg IV push over 1 to 5 minutes.
• Cyclophosphamide
Dosage and route of administration: During VAC chemotherapy: < 3 years of age = 40 mg/kg IV = 3 years of age = 1200 mg/m^2 IV, with MESNA. During maintenance for intermediate-risk participants: oral cyclophosphamide 50 mg/m^2/dose/day (liquid or tablet)

Procedure:
• Surgical Resection
Surgery will be performed for the primary site tumor with the goal of removing tumor cells while maintaining function in the organ or adjacent organs involved.
• Radiation
Radiation therapy will be delivered at approximately week 13 (intermediate risk) or week 19 (high risk) after initiation of chemotherapy. Certain patients will receive radiation at week 4.

Drug:
• Bevacizumab
Dosage and route of administration: 15 mg/kg/dose/day IV.
• Sorafenib
Dosage and route of administration: 90 mg/m^2/dose twice daily.
• Myeloid Growth Factor
If a participant's chemotherapy has been delayed or modified for hematologic toxicity, or if participant experiences a significant life-threatening toxicity due to bone marrow suppression, myeloid growth factor (either filgrastim or peg-filgrastim) will be given per institutional practice. High Risk participants receive filgrastim 5 micrograms/kg/day (maximum 300 micrograms) subcutaneously beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC =750/µL whichever comes last. Sargramostim or peg-filgrastim may not be used.

Procedure:
• Lymph Node Sampling
Clinical and/or imaging evaluation of regional lymph nodes will be conducted pretreatment and preoperatively as part of staging. This will aid in determining the efficacy of this procedure in defining involved lymphatics in "at risk" patients.

Drug:
• Irinotecan
Dosage and Route Administration: During interval compressed therapy - irinotecan 50mg/m^2 IV (maximum dose 100 mg/day) daily x 5.
• Ifosfamide
Dosage and Route of Administration: During interval compressed therapy - Age > 1 year: 1800 mg/m^2/day IV x 5 Age <1 year: treat with 50% doses calculated on a m^2 basis.
• Etoposide
Dosage and Route of Administration: Age >1 year 100 mg/m^2/day IV x 5 Age < 1 year treat with 50% doses calculated on a m^2 basis
• Etoposide Phosphate
Dosage and Route of Administration: Used in substitution for etoposide in participants who experience allergic reaction. It will be administered 100 mg/m^2/day IV.
• Doxorubicin
Dosage and route of Administration: Age =1 year, 37.5 mg/m^2 IV over 1 hour x 2 days Age <1 year, 18.75 mg/m^2 (i.e., a 50% dose reduction) IV over 1 hour x 2 days.
• Dexrazoxane
Dosage and Route of Administration: Dexrazoxane dose should be 10x that of doxorubicin. Age =1 year, 375 mg/m^2 IV over 15-30 minutes Age <1 year, 187l.5 mg/m^2 (i.e., a 50% dose reduction) IV over 15-30 minutes.
• ^1^1C-methionine
Participants receive ^1^1C-methionine to relate the distribution, intensity and change in ^1^1C-methionine CTPET imaging of the primary site to tumor control and patient outcome.

Locations

Country	Name	City	State
United States	Cook Children's Medical Center	Fort Worth	Texas
United States	Nemours Children's Clinic	Jacksonville	Florida
United States	University of Florida Proton Therapy Institute	Jacksonville	Florida
United States	St. Jude Children's Research Hospital	Memphis	Tennessee

Sponsors (1)

Lead Sponsor	Collaborator
St. Jude Children's Research Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Event-free survival (intermediate risk arm)	To estimate event-free survival for intermediate risk participants treated by vincristine-dactinomycin-cyclophosphamide (VAC) with the addition of maintenance anti-angiogenic therapy	2 years after last intermediate risk arm enrollment
Secondary	Event-free survival (high risk arm)	To estimate event-free survival for high risk participants.	5 years after last high-risk arm enrollment
Secondary	Rate of false negative and false positive the sentinel lymph node procedure (low and intermediate risk arms)	Estimate the false negative rate and incidence of additional positive lymph nodes in participants undergoing sentinel lymph node biopsy followed by limited nodal dissection.	2 years after last low or intermediate arm enrollment
Secondary	Rate of false negative and false positive the sentinel lymph node procedure (high risk arm)	Estimate the false negative rate and incidence of additional positive lymph nodes in participants undergoing sentinel lymph node biopsy followed by limited nodal dissection.	5 years after last high risk arm enrollment
Secondary	Local failure rate (low and intermediate risk arms)	Maintain a high local control rate in participants treated with surgery and / or limited volume proton and photon radiation without dose escalation	2 years after last low or intermediate risk arm enrollment
Secondary	Local failure rate (high risk arm)	Maintain a high local control rate in participants treated with surgery and / or limited volume proton and photon radiation without dose escalation	5 years after last high risk arm enrollment
Secondary	Patterns of failure (low and intermediate risk arms)	Define the incidence and type of failure in participants who receive risk-adapted local therapy relative to the primary tumor volume	2 years after last low or intermediate risk arm enrollment
Secondary	Patterns of failure (high risk arm)	Define the incidence and type of failure in participants who receive risk-adapted local therapy relative to the primary tumor volume	5 years after last high risk arm enrollment
Secondary	Number of patients that complete all cycles of maintenance chemotherapy (intermediate risk arm)	Establish the feasibility of delivering 4 cycles of maintenance antiangiogenic chemotherapy (bevacizumab / sorafenib / low dose cyclophosphamide) in intermediate risk patients following standard chemotherapy.	2 years after last low or intermediate risk arm enrollment
Secondary	Number of patients that complete all cycles of maintenance chemotherapy (high risk arm)	Establish the feasibility of delivering 4 cycles of maintenance antiangiogenic chemotherapy (bevacizumab / sorafenib / low dose cyclophosphamide) in high risk patients following standard chemotherapy.	5 years after last high risk arm enrollment
Secondary	Incidence of CTC grade 3 and higher toxicities related to proton bream therapy (low and intermediate and high risk arms)	Define the incidence of CTC grade 3 and higher toxicities (and specific grade 1-2 toxicities) related to proton beam therapy.	2 years after last enrollment

External Links

•   Clinical Trials Open at St. Jude
•   St. Jude Children's Research Hospital